Brokers Set Expectations for Actinium Pharmaceuticals, Inc.'s FY2026 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - HC Wainwright increased their FY2026 earnings per share estimates for Actinium Pharmaceuticals in a research note issued on Monday, April 29th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of $4.10 per share for the year, up from their prior estimate of $3.86. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Actinium Pharmaceuticals' current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals' FY2027 earnings at $7.94 EPS and FY2028 earnings at $10.75 EPS.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last issued its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter.

Several other research analysts have also issued reports on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday. StockNews.com raised Actinium Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday. Finally, Maxim Group lifted their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $25.72.

Actinium Pharmaceuticals Price Performance

NYSEAMERICAN ATNM traded up $0.31 during trading hours on Tuesday, reaching $7.69. 282,654 shares of the company's stock were exchanged, compared to its average volume of 321,759. The firm has a market cap of $226.09 million, a PE ratio of -4.20 and a beta of 0.01. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brandywine Global Investment Management LLC bought a new position in Actinium Pharmaceuticals during the third quarter worth $1,033,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock valued at $101,000 after purchasing an additional 3,175 shares during the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at about $78,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.